(via TheNewswire)

Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced continued advancement in participant enrollment for its clinical trial assessing its innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ ASD ”).

The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period.

SCI-210 is an innovative proprietary combination of cannabidiol (“ CBD ”) and CannAmide™, the Company’s Palmitoylethanolamide-based proprietary formulation. The treatment is being assessed for its ability to alleviate symptoms associated with ASD and to determine whether the dual ‑ compound approach offers advantages beyond CBD monotherapy .

The study is designed to evaluate the efficacy and safety of SCI-210 compared with CBD monotherapy. The trial’s primary efficacy endpoints include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) assessment conducted by a clinician, and determination of the optimal therapeutic dose.

The ongoing clinical trial is a key element of NeuroThera’s program for SCI-210 and reflects the Company’s broader commitment to advancing innovative treatments for neurological and neurodevelopmental conditions. The study was designed in collaboration with the National Autism Research Center, a leading authority on autism research in Israel.

Subject to the successful completion of the clinical development program and receipt of applicable regulatory approvals, the Company intends to pursue the commercialization of SCI-210, initially in Israel and subsequently in additional markets.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information can often be identified by words such as "may," "potential," "could," "expects," "anticipates," "intends," "believes" and similar expressions.

Forward-looking information in this news release includes, without limitation, statements regarding: the continued progress and timing of participant enrollment in the Company's clinical trial of SCI-210, including the Company's ability to enroll the planned total of 60 children; the design, conduct, duration and completion of the clinical trial, including the 20-week treatment period; the potential of SCI-210 to alleviate symptoms associated with autism spectrum disorder; whether the combination of CBD and CannAmide™ offers advantages over CBD monotherapy; the ability of the trial to demonstrate the efficacy and safety of SCI-210, to meet its primary efficacy endpoints and to determine an optimal therapeutic dose; the Company's broader development plans for SCI-210 and other treatments for neurological and neurodevelopmental conditions; and the Company's intention to pursue regulatory approval and commercialization of SCI-210, initially in Israel and subsequently in additional markets.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Such factors include, without limitation: the risk that enrollment in the clinical trial will be slower than anticipated , will not reach the planned number of participants, or that participants will withdraw prior to completion ; the risk that the clinical trial will be delayed, suspended or terminated for safety, regulatory, operational or other reasons; the risk that SCI-210 will not demonstrate efficacy or safety in the trial, will not meet its primary endpoints, or will not demonstrate an advantage over CBD monotherapy; the inherent uncertainty of pediatric clinical trials in autism spectrum disorder, including reliance on parent-reported and clinician-assessed outcome measures and the potential for a significant placebo response; the risk that an optimal therapeutic dose will not be identified ; the risk that results from this trial will not be predictive of results in later-stage or larger trials , or will not support regulatory approval ; the Company's reliance on Soroka Medical Center, the National Autism Research Center and other third parties for the conduct of the trial , manufacturing of clinical supply and related activities; the risk that regulatory approvals required to commercialize SCI-210 in Israel or any other jurisdiction will not be obtained on a timely basis, or at all , including uncertainty regarding the regulatory treatment of cannabinoid-based products; the Company's ability to obtain, maintain and enforce intellectual property protection for SCI-210 and CannAmide™; the Company's need for additional financing to complete the clinical development program and the risk that such financing will not be available on acceptable terms, or at all; competition from other companies developing treatments for autism spectrum disorder , some of which have substantially greater resources or are at more advanced stages of development; geopolitical, security and other conditions in Israel, where the clinical trial is being conducted ; the Company's status as a subsidiary of SciSparc Ltd. and the potential for conflicts of interest or changes in SciSparc's strategy or ownership; and general economic, market and business conditions, and the risks described in the Company's continuous disclosure documents filed on SEDAR+ ( www.sedarplus.ca ).

Readers are cautioned that the foregoing list of factors is not exhaustive. These statements are not guarantees of future performance and undue reliance should not be placed on them. The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.